Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 16Gynecologic 4Genitourinary 4CNS 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Pleural Effusion, Malignant 1Neoplasm Metastasis 1

Interventions

Carboplatin 41Cisplatin 40Paclitaxel 35Radiotherapy 32Docetaxel 19Pemetrexed 18Gemcitabine 17Etoposide 17Bevacizumab 11Radiosurgery 10Magnetic Resonance Spectroscopy 9Ramucirumab 8durvalumab 7Taxes 7Cetuximab 7pembrolizumab 6Specimen Handling 6Erlotinib Hydrochloride 6Irinotecan 5Gene Expression Profiling 5Filgrastim 5cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Amplified Fragment Length Polymorphism Analysis 4tremelimumab 3osimertinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Bleomycin × Thoracic × Clear all
NCT00002872 2023-06-22

Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions

Eastern Cooperative Oncology Group

Phase 3 Completed
480 enrolled
Thoracic

Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡